DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United States
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
IQV logo

IQVIA Holdings Inc. Stock Price

NYSE:IQV Community·US$43.1b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 38 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

IQV Share Price Performance

US$0
-185.97 (-100.00%)
​
US$275.17
Fair Value
US$0
-185.97 (-100.00%)
​
Price US$0
Mon, 24 Aug 26
Fair ValueUS$275.17
Share Pricen/a

IQV Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value US$275.17 4.9% undervalued intrinsic discount

Analyst Commentary Highlights Resilience and Upgraded Valuation Outlook for IQVIA Holdings

0users have liked this narrative
0users have commented on this narrative
18users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value US$243.75 7.4% overvalued intrinsic discount

Rising Regulatory Burdens And High Debt Will Limit Operations

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value US$300 12.7% undervalued intrinsic discount

NVIDIA Partnership And AI Deployment Will Fuel Healthcare Digitization

0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
IQV logo
IQVIA Holdings
4.9% undervalued intrinsic discount

Analyst Commentary Highlights Resilience and Upgraded Valuation Outlook for IQVIA Holdings

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 24 Aug
Read Narrative
IQV logo
IQVIA Holdings
7.4% overvalued intrinsic discount

Rising Regulatory Burdens And High Debt Will Limit Operations

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 7 Sep
Read Narrative
IQV logo
IQVIA Holdings
12.7% undervalued intrinsic discount

NVIDIA Partnership And AI Deployment Will Fuel Healthcare Digitization

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 10 Aug
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystLowTarget
IQV logo

IQV: Future Returns Will Hinge On AI Trial Adoption And Margin Resilience

Fair Value: US$243.75 7.4% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystConsensusTarget
IQV logo

IQV: CRO Recovery And AI Strength Will Support Measured Earnings Reacceleration

Fair Value: US$275.17 4.9% undervalued intrinsic discount
18 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystHighTarget
IQV logo

IQV: Tech Differentiation And CRO Inflection Will Support Backlog And Margin Recovery

Fair Value: US$300 12.7% undervalued intrinsic discount
4 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Solid track record and good value.

2 Risks
3 Rewards
View Full Analysis

IQVIA Holdings Inc. Key Details

US$17.0b

Revenue

US$11.4b

Cost of Revenue

US$5.6b

Gross Profit

US$4.2b

Other Expenses

US$1.4b

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
8.35
32.97%
8.10%
254.1%
View Full Analysis

About IQV

Founded
n/a
Employees
94000
CEO
Ari Bousbib
WebsiteView website
www.iqvia.com

IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients’ outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.

Recent IQV News & Updates

User avatar
Narrative Update • Sep 07

IQV: Future Returns Will Hinge On AI Trial Adoption And Margin Resilience

The analyst fair value estimate for IQVIA Holdings has shifted from $200.00 to $243.75, reflecting updated views that recent Q2 earnings, stronger CRO activity, improving bookings trends, and the company's technology positioning support a higher long-term price target profile across the Street. Analyst Commentary Street research around IQVIA Holdings following the Q2 report has been active, with many firms updating price targets and revisiting their views on the stock.

Recent updates

No updates

IQVIA Holdings Inc. Competitors

TMO logo

Thermo Fisher Scientific

Symbol: NYSE:TMO
Market cap: US$225.5b
AMGN logo

Amgen

Symbol: NasdaqGS:AMGN
Market cap: US$204.0b
GILD logo

Gilead Sciences

Symbol: NasdaqGS:GILD
Market cap: US$178.2b
PFE logo

Pfizer

Symbol: NYSE:PFE
Market cap: US$158.0b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide